AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02019082 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the intervention procedure was the same as that the ES group, but the current intensity was zero
Study NCT03116321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eslicarbazepine acetate (ESL)
Description: Oral Tablet of 800 mg and 200 mg of ESL
Study NCT03116321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Description: Oral Tablet of 800 mg and 200 mg of ESL
Study NCT00004418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyceryl trierucate/glyceryl trioleate
Description: Administration of glyceryl trierucate/glyceryl trioleate
Study NCT02072720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
Study NCT03755284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacral Massage
Description: ● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
Study NCT02503631 — intervention group
Intervention type: DEVICE
Intervention: Stool Sample Collection Kit
Description: Stool sample collection kit
Study NCT02472119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rusks made of wheat flour enzymatically treated
Description: 100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
Study NCT02472119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rusks made of wheat flour not enzimatically modified
Description: 100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
Study NCT02472119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: gluten-free diet
Study NCT02472119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: gluten-free diet
Study NCT04367025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab: 200mg,iv drip for 1h,d1,q3w
Study NCT04367025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
Study NCT04367025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
Study NCT04367025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1:40\~60mg Bid, d1\~14, q3w;
Study NCT04729556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sericin and chitosan cream
Description: A novel film-forming cream containing sericin and chitosan
Study NCT04729556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sericin and chitosan cream
Description: A novel film-forming cream containing sericin and chitosan
Study NCT02084784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
Study NCT02084784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
Study NCT02346500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transrectal Ultrasound
Description: The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
Study NCT02991937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: 24 hours of IV antibiotic administration
Study NCT02991937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Treatment
Description: Appendectomy
Study NCT00414960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: 500 mg po QD for 6 months
Study NCT00414960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po QD for 6 months
Study NCT03259490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin/metformin HCl
Description: Once daily
Study NCT03259490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Once daily
Study NCT03259490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Once daily
Study NCT03259490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl
Description: Once daily
Study NCT02942316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupil dilation reflex measurement
Description: Pupillometry (PDR) at four standardized times perioperatively~* after induction, before opioid administration~* after opioid administration, steady state~* surgical incision~* end of procedure
Study NCT02024204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 230mcg for 3 Months
Study NCT02024204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Current Treatment or no treatment
Description: Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
Study NCT03889652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oct scans
Description: Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
Study NCT00948350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: awake intubation
Description: two anesthesia techniques
Study NCT02894866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
Study NCT02024204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 21mcg for 3 Months
Study NCT03455309 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3A
Description: Single dose administered by intramuscular injection
Study NCT03455309 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered by intramuscular injection
Study NCT03420716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yogurt
Study NCT00815906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: IV, Single dose
Study NCT00815906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: SC, Single dose
Study NCT02240537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
Study NCT02240537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-MPI-03
Description: Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
Study NCT02240537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide
Description: Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration.
Study NCT00740168 — intervention group
Intervention type: DRUG
Intervention: bevacizumab treatment
Description: single infusion 10 mg/kg
Study NCT00647868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
Study NCT03188679 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: amniocentesis
Description: mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
Study NCT02995590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized He3
Description: Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
Study NCT01638611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIP2B
Description: Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
Study NCT01638611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
Study NCT04501679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
Study NCT00009217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol-Haloperidol
Description: Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
Study NCT00009217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Haloperidol-Placebo
Description: Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
Study NCT04501679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo as SC injection.
Study NCT04922749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MULTI+
Description: MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
Study NCT04255836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
Study NCT00939419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health workers TB care group
Description: Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
Study NCT04255836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the first line chemotherapy for metastatic NSCLC
Description: paclitaxel+carboplatin or pemetrexed+cisplatin
Study NCT04255836 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: SBRT total doses of 50-60Gy/≤10F
Study NCT04761029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RIIS
Description: unilateral Rhomboid intercostal and subserratus block
Study NCT04761029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: intravenous patient-controlled analgesia (tramadol)
Study NCT04761029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: intravenous patient-controlled analgesia (tramadol)
Study NCT02742350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT - POWERbreathe Plus Light Resistance®, SP, BR
Description: POWERbreathe Plus Light Resistance®, SP, BR
Study NCT00510224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin
Description: Sandostatin 30mg intramuscular every 28 days
Study NCT04958616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test.
Description: Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
Study NCT02509494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
Study NCT00939419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community health workers TB care group
Description: Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
Study NCT00939419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered treatment group
Description: Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
Study NCT01340261 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
Study NCT03926884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Three-seeds mixture
Description: mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
Study NCT00251641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
Study NCT00251641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
Study NCT02135120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal epidural anesthesia technique with intrathecal morphine
Study NCT02135120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block
Study NCT02135120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
Study NCT02110017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI social cognition task
Description: fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
Study NCT01976013 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coaguchek
Description: The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
Study NCT03926884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: warm water with negligible amount of the three-seeds mixture
Study NCT01153451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Email Notification
Description: BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
Study NCT02488980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
Study NCT02488980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Description: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
Study NCT02488980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for three days followed by placebo once a week for 24 weeks
Study NCT03003637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
Study NCT03003637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
Study NCT02174393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal Peel
Description: Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
Study NCT02174393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen
Study NCT02174393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Microneedling Skin Care
Description: On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)
Study NCT02174393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Universal Peel Skin Care
Description: * Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening
Study NCT02468297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Acupunture Shoes
Description: Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy.